With the belief that patients deserve better than the current standard of care, the Arcutis team brings a sense of urgency, simplifying disease management and optimizing drug efficacy, safety, and tolerability to meet the needs of healthcare providers and patients.
Healthcare professionals and patients alike are frustrated by stagnant R&D efforts, difficulties managing complex disease, and lack of innovation in topical dermatology products.
We believe patients deserve better. Better treatments. Better quality of life. That’s why we’re here.
At Arcutis, meaningful innovation means focusing on unmet needs in the treatment of immune-mediated skin diseases. With deep medical dermatology development expertise and a unique dermatology drug development platform, we’re committed to meaningful advances—innovation that solves the most persistent challenges of patients, their families, and the healthcare professionals who care for them.
Our dermatology drug development platform includes a robust pipeline for a range of inflammatory dermatological conditions with multiple clinical programs, and with several significant clinical data readouts anticipated throughout the next 24 months. Arcutis applies meaningful innovation as we strive to simplify the management of skin disease for these patients.